MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/19.12.25 | Market Closed - Börse Stuttgart 20:17:57 05/07/2024 BST | ||
| 0.46 EUR | 0.00% |
|
| 3 months | -45.24% | ||
| 6 months | -66.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.46 | 0.00% |
| 04/07/24 | 0.46 | -8.00% |
| 03/07/24 | 0.5 | +6.38% |
| 02/07/24 | 0.47 | +6.82% |
| 01/07/24 | 0.44 | -4.35% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 08:17 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1Z0Z |
| ISIN | DE000ME1Z0Z8 |
| Date issued | 12/10/2023 |
| Strike | 100 $ |
| Maturity | 19/12/2025 (532 Days) |
| Parity | 10 : 1 |
| Emission price | 1.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.04 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.01 € |
| Spread % | 2.13% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
